166 related articles for article (PubMed ID: 3688278)
1. Neuroleptic responsivity of negative and positive symptoms in schizophrenia.
Breier A; Wolkowitz OM; Doran AR; Roy A; Boronow J; Hommer DW; Pickar D
Am J Psychiatry; 1987 Dec; 144(12):1549-55. PubMed ID: 3688278
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
Pickar D; Labarca R; Doran AR; Wolkowitz OM; Roy A; Breier A; Linnoila M; Paul SM
Arch Gen Psychiatry; 1986 Jul; 43(7):669-76. PubMed ID: 3718170
[TBL] [Abstract][Full Text] [Related]
3. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
4. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Kirkpatrick B; Carpenter WT; Maeda K; Buchanan RW; Breier A; Tamminga CA
Biol Psychiatry; 1992 Dec; 32(11):1049-54. PubMed ID: 1467385
[TBL] [Abstract][Full Text] [Related]
5. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
Singh H; Hunt JI; Vitiello B; Simpson GM
J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
[TBL] [Abstract][Full Text] [Related]
6. Methylphenidate challenge as a predictor of relapse in schizophrenia.
Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
[TBL] [Abstract][Full Text] [Related]
7. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Wistedt B; Palmstierna T
J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
[TBL] [Abstract][Full Text] [Related]
8. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
[TBL] [Abstract][Full Text] [Related]
9. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.
Wistedt B
Acta Psychiatr Scand; 1981 Jul; 64(1):65-84. PubMed ID: 7032224
[TBL] [Abstract][Full Text] [Related]
10. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine.
Litman RE; Su TP; Potter WZ; Hong WW; Pickar D
Br J Psychiatry; 1996 May; 168(5):571-9. PubMed ID: 8733795
[TBL] [Abstract][Full Text] [Related]
11. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.
Gardos G; Cole JO; Rapkin RM; LaBrie RA; Baquelod E; Moore P; Sovner R; Doyle J
Arch Gen Psychiatry; 1984 Nov; 41(11):1030-5. PubMed ID: 6149737
[TBL] [Abstract][Full Text] [Related]
12. [Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].
Wolf MA; Bailly L; Diener JM; Martinet JP; Peretti S; Garneau Y
Encephale; 1991; 17(4):255-61. PubMed ID: 1683626
[TBL] [Abstract][Full Text] [Related]
13. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients.
Iqbal MJ; Young MA; Charles J; Elgart B; Von Greiff H; Simpson GM
J Clin Psychiatry; 1978 Apr; 39(4):375-9. PubMed ID: 580285
[TBL] [Abstract][Full Text] [Related]
14. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.
Saletu B; Küfferle B; Grünberger J; Földes P; Topitz A; Anderer P
Neuropsychobiology; 1994; 29(3):125-35. PubMed ID: 7912819
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.
Pickar D; Owen RR; Litman RE; Konicki E; Gutierrez R; Rapaport MH
Arch Gen Psychiatry; 1992 May; 49(5):345-53. PubMed ID: 1375019
[TBL] [Abstract][Full Text] [Related]
16. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
17. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
Ben Hadj Ali B; Dogui M; Ben Ammou S; Lôo H
Encephale; 1995; 21(3):209-15. PubMed ID: 7649071
[TBL] [Abstract][Full Text] [Related]
18. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
Marder SR; Wirshing WC; Van Putten T; Mintz J; McKenzie J; Johnston-Cronk K; Lebell M; Liberman RP
Arch Gen Psychiatry; 1994 Apr; 51(4):280-7. PubMed ID: 8161288
[TBL] [Abstract][Full Text] [Related]
19. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
[TBL] [Abstract][Full Text] [Related]
20. High vs standard dosage fluphenazine HCL in acute schizophrenia.
Donlon PT; Meadow A; Tupin JP; Wahba M
J Clin Psychiatry; 1978 Nov; 39(11):800-4. PubMed ID: 363702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
